Evaluation of Health and Lifestyle Tool is launched in Sweden

Region Skane is starting a new clinical trial of Evaluation of Health and Lifestyle Tool.

The overall aim of the study is to observe the natural pattern of usage and metabolic outcomes in patients with type 2 diabetes who had access to the new digital tool as a stand-alone support in addition to usual care. The tool is based on self-affirmation theory and has large emphasis on self-reflection to enable sustainable lifestyle changes. The changes in HbA1c, reflecting long-term blood glucose, will be evaluated in patients with type 2 diabetes.

The clinical trial started in January 1, 2017 and will continue throughout December 31, 2021.

Change of long-term blood glucose concentration measured as glycated hemoglobin at one year will be primary outcome measure. Intraindividual change of long-term blood glucose concentration measured as glycated hemoglobin (HbA1c) at one year relative to baseline between participants who use the tool as recommended and matched controls on usual care.

The inclusion parameters are:

  • Patients with type 2 diabetes at or above 35 years of age
  • HbA1C at 52 mmol/mol or above
  • Diagnosis of diabetes mellitus was based on prior documentation or treatment with anti-hyperglycemic medication

The contacts and locations are the Clinical Research Center, Malmö, Sweden.

For more details: https://ichgcp.net/clinical-trials-registry/NCT04691973.

Clinical Research News

Upcoming Clinical Trials